Targeting leukotrienes for the treatment of COPD?

Inflammation and Allergy - Drug Targets

Volumn 8, Issue 4, 2009, Pages 297-306

  Drakatos, Panagis ^a   Lykouras, Dimosthenis ^a   Sampsonas, Fotis ^a   Karkoulias, Kiriakos ^a   Spiropoulos, Kostas ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

5 lipoxygenase activating protein inhibitors; Antileukotriene agents cysteinyl leukotrienes; LTB 4; Montelukast; Pranlukast; Zafirlukast; Zileuton

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; ARACHIDONATE 5 LIPOXYGENASE; BIMOSIAMOSE; CORTICOSTEROID; FOOD ADDITIVE; INTERLEUKIN 10; LEUKOTRIENE; LEUKOTRIENE B4; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; MONTELUKAST; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; PRANLUKAST; THEOPHYLLINE; VERLUKAST; WARFARIN; ZAFIRLUKAST; ZILEUTON;

ABDOMINAL PAIN; ARTICLE; ASTHMA; BLOOD VESSEL PERMEABILITY; BRONCHOSPASM; CD8+ T LYMPHOCYTE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COUGHING; DIARRHEA; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DYSPEPSIA; EVENING DOSAGE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFLAMMATORY CELL; LARYNGITIS; LIVER DYSFUNCTION; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; MACROPHAGE FUNCTION; MORBIDITY; NAUSEA; NONHUMAN; OTITIS; PATHOGENESIS; PHARYNGITIS; RASH; SINUSITIS; SORE THROAT; TOXIC HEPATITIS; VOMITING;

ACETATES; ARACHIDONATE 5-LIPOXYGENASE; BRONCHOCONSTRICTION; CAPILLARY PERMEABILITY; CARRIER PROTEINS; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CHROMONES; EOSINOPHILS; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; MEMBRANE PROTEINS; NEUTROPHILS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLINES; TOSYL COMPOUNDS;

EID: 70349690768     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152809789352177     Document Type: Article

References (118)

1. Celli, B.R.; MacNee, W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J., 2004, 23, 932-46.
2. Lancaster, T.; Stead, L.; Silagy, C.; Sowden, A. Improving the treatment of tobacco dependence. Br. Med. J., 2000, 321, 355-8.
3. National Institute for Clinical Excellence. Chronic obstructive pulmonary disease, NICE, 2004, 12, 5-52.
4. National Heart, Lung and Blood Institute, World Health Organization. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, NHLBI/WHO, Workshop Report, Publication No. 2701, National Institutes of Health, National Heart, Lung and Blood Institute, Bethesda, MD, 2001.
5. Barnes, P.J. Mechanisms in COPD differences from asthma. Chest, 2000, 117, 10S-14S.
6. Devereux, G. ABC of chronic obstructive pulmonary disease. Definition, epidemiology, and risk factors. B. M. J., 2006, 332, 1142-3.
7. Pauwels, R.A.; Buist, A.S.; Calverly, P.M.; Jenkins, C.R.; Hurd, S.S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am. J. Respir. Crit. Care Med., 2001, 163(5), 1256-76.
8. Pesci, A.; Balbi, B.; Majori, M.; Cacciani, J.; Bertacco, S.; Alciato, P.; Donner, C.F. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur. Respir. J., 1998, 12, 380-6.
9. Stockley, R.A. The role of proteinases in the pathogenesis of chronic bronchitis. Am. J. Respir. Crit. Care. Med., 1994, 150, S109-13.
10. Repine, J.E.; Bast, A.; Lankhorst, I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am. J. Respir. Crit. Care. Med., 1997, 156, 341-57.
11. Tetley, T.D. Macrophages and the pathogenesis of COPD. Chest, 2002, 121, 156S-159.
12. Stockley, R.A. Neutrophils and the pathogenesis of COPD. Chest, 2002, 121, 151S-155.
13. Feinmark, S.J.; Lindgren, J.A.; Claesson, H.E.; Malmsten, C.; Samuelsson, B. Stimulation of human leukocyte degranulation by leukotriene B4 and its omega-oxidized metabolites. FEBS Lett., 1981, 136, 141-4.
14. Nohgawa, M.; Sasada, M.; Maeda, A.; Asagoe, A.; Harakawa, N.; Takano, K.; Yamamoto, K.; Okuma, M. Leukotriene B4-activated human endothelial cells promote transendothelial neutrophil migration. J. Leukoc. Biol., 1997, 62, 203-9.
15. Smith, W.B.; Gamble, J.R.; Clark-Lewis, I.; Vadas, M.A. Interleukin-8 induces neutrophil transendothelial migration. Immunol., 1991, 72, 65-72.
16. MacNee, W. ABC of chronic obstructive pulmonary disease. B. M. J., 2006, 332, 1202-4.
17. Barnes, P.J. Small airways in COPD. N. Engl. J. Med., 2004, 350, 2635-7.
18. Hogg, J.C.; Chu, F.; Utokaparch, S.; Woods, R.; Elliott, W.M.; Buzatu, L.; Cherniack, R.M.; Rogers, R.M.; Sciurba, F.C.; Coxson, H.O.; Paré, P.D. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med., 2004, 350, 2645-53.
19. Funk, C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science, 2001, 294, 1871-5.
20. Borgeat, P.; Samuelsson, B. Arachidonic acid metabolism in polymorphonuclear leukocytes: unstable intermediate in formation of dihydroxy acids. Proc. Natl. Acad. Sci., 1979, 76, 3213-7.
21. Weller, P.F.; Lee, C.W.; Foster, D.W.; Corey, E.J.; Austen, K.F.; Lewis, R.A. Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: predominant production of leukotriene C4. Proc. Natl. Acad. Sci., 1983, 80, 7626-30.
22. Henderson, W.R. Eicosanoids and lung inflammation. Am. Rev. Respir. Dis., 1987, 135, 1167-85.
23. Lynch, K.R.; O'Neill, G.P.; Liu, Q.; Dong - Soon, L.M.; Sawyer, N.; Metters, K. M.; Heise, C.E.; O'Dowd, B.F.; Figueroa, D.J.; Sawyer, N.; Nguyen, T.; Im, D.; Stocco, R.; Bellefeuille, J.N.; Abramovitz, M.; Cheng, R.; Williams, D.L.Jr.; Zeng, Z.; Liu, Q.; Ma, L.; Clements, M.K.; Coulombe, N.; Liu, Y.; Austin, C.P.; George, S.R. Characterization of the human cysteinyl leukotriene 2 receptor. Nature, 1999, 399, 789-93.
24. Spector, S.L. Leukotriene inhibitors and antagonists in asthma. Ann. Allergy Asthma Immunol., 1995, 75, 463-74.
25. Busse, W.W. The role of leukotrienes in asthma and allergic rhinitis. Clin. Exp. Allergy, 1996, 26, 868-79.
26. Labat, C.; Ortiz, J.L.; Norel, X.; Gorenne, I.; Verley, J.; Abram, T.S.; Cuthbert, N.J.; Tudhope, S.R.; Norman, P.; Gardiner, P. A second cysteinyl leukotriene receptor in human lung. J. Pharmacol. Exp. Ther., 1992, 263, 800-5. 27 Back, M. Functional characteristics of cysteinyl-leukotriene receptor subtypes. Life Sci., 2002, 71, 611-22.
27. Feldberg, W.; Kelloway, C.H. Liberation of hista- mine and formation of lysolecithin-like substance by cobra venom. J. Physiol., 1938, 94, 187-226.
28. Vachier, I.; Bonnans, C.; Chavis, C.; Farce, M.; Godard, P.; Bousquet, J.; Chanez, P. Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound. J. Allergy Clin. Immunol., 2005, 115, 55-60.
29. Miyahara, S.; Takeda, K.; Miyahara, S.; Taube, C.; Joetham, A.; Koya, T.; Matsubara, S.; Dakhama, A.; Tager, A.M.; Luster, A.D.; Gelfand, E.W. Leukotriene B4 receptor-1 is essential for allergen-mediated recruitment of CD8+ T cells and airway hyperresponsiveness. J. Immunol., 2005, 174, 4979-84.
30. Tager, A.M.; Luster, A.D. BLT1 and BLT2: the leukotriene B(4) receptors. Prostaglandins Leukot. Essent. Fatty Acids, 2003, 69, 123-34.
31. Ott, V.L.; Cambier J.C.; Kappler, J.; Marrack, P.; Swanson, B.J. Mast cell-dependent migration of effector CD8+ T cells through production of leukotriene B4. Nat. Immunol., 2003, 4, 974-81.
32. Taube, C.; Miyahara, N.; Ott, V.; Swanson, B.; Takeda, K.; Loader, J.; Shultz, L.D.; Tager, A.M.; Luster, A.D.; Dakhama, A.; Gelfand, E.W. The leukotriene B4 receptor (BLT1) is required for effector CD8+ T cell-mediated, mast cell-dependent airway hyper-responsiveness. J. Immunol., 2006, 176, 3157.
33. Holgate, S.T.; Bradding, P.; Sampson, A.P. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J. Allergy. Clin. Imunnol., 1996, 98, 1-13.
34. Tan, R.A.; Spector, S.L. Antileukotriene agents. Curr. Opin. Pulm. Med., 1997, 3, 215-20.
35. Samuelsson, B. The discovery of the leukotrienes. Am. J. Respir. Crit. Care. Med., 2000, 161 (suppl), 41-5.
36. Lynch, K.R.; O'Neill, G.P.; Liu, Q.; Im, D-S.; Sawyer, N.; Metters, K.M.; Coulombe, N.; Abramovitz, M.; Gigueros, D.K.; Zeng, Z.; Connolly, B.M.; Bai, C.; Austin, C.P.; Chateauneuf, A.; Stocco, R.; Greig, G.M.; Kargman, S.; Hooks, S.B.; Hosfield, E.; Williams, D.L.Jr.; Ford-Hutchinson, A.W.; Caskey, C.T.; Evans, J.F. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature, 1999, 399, 789-93.
37. McMillan, R.M. Leukotrienes in respiratory disease. Paediatr. Respir. Rev., 2001, 2, 238-44.
38. Carter, G.W.; Young, P.R.; Albert, D.H.; Bouska, J.; Dyer, R.; Bell, R.L.; Summers, J.B.; Brooks, D.W. 5-lipoxygenase inhibitory activity of zileuton. J. Pharmacol. Exp. Ther., 1991, 256, 929-37.
39. O'Driscoll, B.R.; Cromwell, O.; Kay, A.B.; Sputum leukotrienes in obstructive airways diseases. Clin. Exp. Immunol., 1984, 55, 397-404.
40. Wardlaw, A.J.; Hay H.; Cromwell, O.; Collins, J.V.; Kay, A.B. Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J. Allergy Clin. Immunol., 1989, 84, 19-26.
41. Shindo, K.; Matsumoto, Y.; Hirai, Y.; Sumitomo, M.; Amano, T.; Miyakawa, K.; Matsumura, M.; Mizuno, T. Measurement of leukotriene B4 in arterial blood of asthmatic patients during wheezing attacks. J. Intern. Med., 1990, 228, 91-6.
42. Meltzer, S.S.; Hasday, J.D.; Cohn, J.; Bleecker, E.R. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am. J. Respir. Crit. Care Med., 1996, 153, 931-5.
43. 4 lipid chemoattractant receptor BLT1 defines antigen-primed T cells in humans. Blood, 2006, 107, 444-53.
44. 4: novel interactions in the persistence and progression of asthma. J. Allergy Clin. Immunol., 2006, 117, 577-82.
45. Shaw, R.J.; Fitzharris, P.; Cromwell, O.; Wardlaw, A.J.; Kay, A.B. Allergen-induced release of sulphidopeptide leukotrienes (SRS-A) and LTB4 in allergic rhinitis. Allergy, 1985, 40, 1-6.
46. Meslier, N.; Braunstein, G.; Lacronique, J.; Dessanges, J.F.; Rakotosihanaka, F.; Devillier, P.; Lockhart, A.; Mencia-Huerta, J.M.; Boushey, A.J. Local cellular and humoral responses to antigenic and distilled water challenge in subjects with allergic rhinitis. Am. Rev. Respir. Dis., 1988, 137, 617-24.
47. Knapp, H.R. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N. Engl. J. Med., 1990, 323, 1745-8.
48. Kumar, N.S.; Schaefer, P.A.; Lark, G.; Frieri, M. Late phase response during nasal challenge: effect of astemizole on leukotriene B4 levels. Allergy Asthma Proc., 1996, 17, 93-9.
49. Ruzicka, T.; Simmet, T.; Peskar, B.A.; Ring, J. Skin levels of arachidonic acid-derived inflammatory mediators and histamine in atopic dermatitis and psoriasis. J. Invest. Dermatol., 1986, 86, 105-8.
50. Fogh, K.; Herlin, T.; Kragballe, K. Eicosanoids in skin of patients with atopic dermatitis: prostaglandin E2 and leukotriene B4 are present in biologically active concentrations. J. Allergy. Clin. Immunol., 1989, 83, 450-5.
51. Reilly, D.M.; Parslew, R.; Sharpe, G.R.; Powell, S.; Green, M.R. Inflammatory mediators in normal, sensitive and diseased skin types. Acta Derm. Venereol., 2000, 80, 171-4.
52. Nathan, H.; Naveh, N.; Meyer, E. Levels of prostaglandin E2 and leukotriene B4 in tears of vernal conjunctivitis patients during a therapeutic trial with indomethacin. Doc. Ophthalmol., 1994, 85, 247-57.
53. Akman, A.; Irkeç, M.; Orhan, M. Effects of lodoxamide, disodium cromoglycate and fluorometholone on tear leukotriene levels in vernal keratoconjunctivitis. Eye, 1998, 12, 291-5.
54. Hashimoto, A.; Endo, H.; Hayashi, I.; Murakami, Y.; Kitasato, H.; Kono, S.; Matsui, T.; Tanaka, S.; Nishimura, A.; Urabe, K.; Itoman, M.; Kondo, H. Differential expression of leukotriene B4 receptor subtypes (BLT1 and BLT2) in human synovial tissues and synovial fluid leukocytes of patients with rheumatoid arthritis. J. Rheumatol., 2003, 30, 1712-8.
55. Seggev, J.S.; Thornton, W.H.Jr.; Edes, T.E. Serum leukotriene B4 levels in patients with obstructive pulmonary disease. Chest, 1991, 99, 289-91.
56. Kostikas, K.; Gaga, M.; Papatheodorou, G.; Karamanis, T.; Orphanidou, D.; Loukides, S. Leukotriene B4 in exhaled breath condensate and sputum supernatant in patients with COPD and asthma. Chest, 2005, 127, 1553-9.
57. Medoff, B.D.; Seung, E.; Wain, J.C.; Means, T.K.; Campanella, G.S.; Islam, S.A.; Thomas, S.Y.; Ginns, S.C.; Grabie, N.; Lichtman, A.H.; Tager, A.M.; Luster, A.D. BLT1-mediated T cell trafficking is critical for rejection and obliterative bronchiolitis after lung transplantation. J. Exp. Med., 2005, 202, 97-110.
58. Wilborn, J.; Bailie, M.; Coffey, M.; Burdick, M.; Strieter, R.; Peters-Golden, M. Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J. Clin. Invest., 1996, 97, 1827-36.
59. Kowal-Bielecka, O.; Distler, O.; Kowal, K.; Siergiejko, K.;. Chwiecko, J.; Sulik, A.; Gay, R.E.; Lukaszyk, A.B.; Gay, S.; Sierakowski, S. Elevated levels of leukotriene B4 and leukotriene E4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease. Arthritis Rheum., 2003, 48, 1639-46.
60. Montuschi, P.; Kharitonov, S.A.; Ciabattoni, G.; Barnes, P.J. Exhaled leukotrienes and prostaglandins in COPD. Thorax, 2003, 58, 585-8.
61. Biernacki, W.A.; Kharitonov, S.A.; Barnes, P.J. Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbation of COPD. Thorax, 2003, 58, 294-8.
62. Hicks, A.; Monkarsh, S.P.; Hoffman, A.F.; Goodnow, R.Jr. Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments. Expert Opin. Investig. Drugs, 2007, 16, 1909-20. 64 Singulair Tablets and Chewable Tablets (montelukast sodium). Physicians' Desk Reference, 53rd ed.; Thomson PDR Press: Montvale, N. J., 1999, pp. 1886-9.
63. Actis, G.C.; Bugianesi, E.; Ottobrelli, A.; Rizzetto, M. Fatal liver failure following food supplements during chronic treatment with montelukast. Dig. Liver Dis., 2007, 39, 953-5.
64. Spector, S.L.; and Antileukotriene working group. Ann. Allergy Asthma Immunol., 2001, 86, 18-23.
65. Singulair. Manufacturer's prescribing information.; Merck and Co: Whitehouse Station. N. J., 1999.
66. Jones, T.R.; Labelle, M.; Belley, M.; Champion, E.; Charette, L.; Evans, J.; Ford Hutchinson, A.W.; Gauthier, J.Y.; J_Lord, A.; Masson, P. Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Can. J. Physiol. Pharmacol., 1995, 73, 191-5.
67. Reinus, J.F.; Persky, P.; Burkiewicz, J.S.; Quan, D.; Bass, N.M.; Davern, T.J. Severe Liver injury after treatment with the leukotriene receptor antagonist zafirlukast. Ann. Intern. Med., 2000, 133, 964-8.
68. Moles, J.R.; Primo, J.; Fernandez, J.M.; Hinojosa, J.E. Acute hepatocellular injury associated with zafirlukast. J. Hepatol., 2001, 35, 541-2.
69. Wooltorton, E. Asthma drug zafirlukast (Accolate): serious hepatic events. Can. Med. Assoc. J., 2004, 170, 1668.
70. Adkins, J.C.; Brogden, R.N. Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma. Drugs, 1998, 55, 121-44.
71. Accolate: Manufacturer's prescribing information.; Zeneca Pharmaceuticals: Carolina, Puerto Rico 1999.
72. Dunn, C.J.; Goa, K.L. Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma. Drugs, 2001, 61, 285-315.
73. Accolate (zafirIukast tablets). Physicians' Desk Reference. 53rd Ed.; Thomson PDR Press: Montvale, N.J., 1999, pp. 3402-04.
74. Keam, S.J.; Lyseng-Williamson, K.A.; Goa, K.L. Pranlukast: a review of its use in the management of asthma. Drugs, 2003, 63, 991-1019.
75. Horiguchi, T.; Kondo, R.; Miyazaki, J.; Shiga, M.; Sugiyama, M.; Hirose, M.; Tachikawa, S. Clinical effects of long-term administration of pranlukast, a leukotriene receptor antagonist, on adult patients with bronchial asthma. Nihon Kokyuki Gakkai Zasshi., 2003, 41, 696-703.
76. Obase, Y.; Shimoda, T.; Tomari, S.; Mitsuta, K.; Obase, Y.; Fukushima, C.; Matsuse, H.; Kohno, S. Efficacy and safety of long-term treatment of asthmatic patients with pranlukast, a cysteinyl-leukotriene-receptor antagonist: four-year followup study. Ann. Allergy. Asthma Immunol., 2001, 87, 43-7.
77. Yoo, S.H.; Park, S.H.; Song, J.S.; Kang, H.S.; Park, C.S.; Yoo, J.H.; Choi, B. W.; Hahn, M.H. Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial. Respirology, 2001, 6, 15-21.
78. Yoshida, S.; Ishizaki, Y.; Onuma, K.; Shoji, T.; Nakagawa, H.; Amayasu, H. Effect of pranlukast on bronchial inflammation in patients with asthma. Clin. Exp. Allergy, 2000, 30, 1008-14.
79. Yanagawa, H.; Sugita, A.; Azuma, M.; Ogawa, H.; Kitamuro, C.; Yoneda, K.; Shinkawa, K.; Tani, K.; Sone, S. Long-term follow-up of pulmonary function in bronchial asthma patients treated with pranlukast. Lung, 2004, 182, 51-8.
80. McGill, K.A.; Busse, W.W. Zileuton. Lancet, 1996, 348, 519-24.
81. Anonymous. Med. Lett., 1997, 39, 18.
82. Lazarus, S.C.; Lee, T.; Kemp, J.P.; Wenzel, S.; Dubé, L.M.; Ochs, R.F.; Carpentier, P.J.; Lancaster, J.F. Safety and clinical efficacy of zileuton in patients with chronic asthma. Am. J. Manag. Care, 1998, 4, 841-8.
83. Lu, M.C.; Dube, L.M.; Lancaster, J. Allergy Clin. Immunol., 1996, 98, 859-71.
84. Valacer, D. J. J. Natl. Med. Assoc., 1999, 91, 26S-39S.
85. Israel, E.; Cohn, J.; Dube, L.; Drazen, J. M. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA, 1996, 275, 931-6.
86. Zyflo Filmtab (zileuton tablets). Physicians' Desk Reference, 53rd ed.; Thomson PDR Press: Montvale, NJ, 1999, pp. 481-3.
87. Yuksel, H.; Ozbilgin, K.; Coskun, S.; Tuglu, I. Protective effect of leukotriene receptor antagonist montelukast on smoking-induced lung injury in wistar rats. Acta Med. Okayama, 2003, 57(1), 13-9.
88. Cazzola, M.; Centanni, S.; Boveri, B.; Carlucci, P.; Santus, P.; DiMarco, F.; Allegra, L. Lung function improvement in smokers suffering from COPD with zafirlukast, a CysLT1-reseptor antagonist. Pulm. Pharmacol. Ther., 2000, 13, 301-5.
89. Cazzola, M.; Centanni, S.; Boveri, B.; Di Marco, F.; Santus, P.; Matera, MG.; Allegra, L. Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatment in asthma and chronic obstructive pulmonary disease. Respiration, 2001, 68, 452-9.
90. Nannini, L.J.; Flores, D.M. Bronchodilator effect of zafirlukast in subjects with chronic obstructive pulmonary disease. Pulm.Pharmacol. Ther., 2003, 16, 307-11.
91. Leff, J.A.; Busse, W.W.; Pearlman, D.; Bronsky, E.A.; Kemp, J.; Hendeles, L.; Dockhorn, R.; Kundu, S.; Zhang, J.; Seidenberg, BC.; Reis, T. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N. Engl. J. Med., 1998, 339, 147-52.
92. Zühlke, I.E.; Kanniess, F.; Richter, K.; Nielsen-Gode, D.; Böhme, S.; Jörres, R.A.; Magnussen, H. Montelukast attenuates the airway response to hypertonic saline in moderate-to-severe COPD. Eur. Respir. J., 2003, 22, 926-30.
93. Rubenstein, I.; Kumar, B.; Schriever, C. Long-term montelukast therapy in moderate to severe COPD - a preliminary observation. Respir. Med, 2004, 98, 134-8.
94. Celic, P.; Sakar, A.; Havlucu, Y.; Yuksel, H.; Turkdogan, P.; Yorgancioglu, A. Short-term effects of montelukast in stable patients with moderate to severe COPD. Respir. Med., 2005, 99, 444-50.
95. Luster, A.D. Chemokines - chemotactic cytokines that mediate inflammation. N. Engl. J. Med., 1998, 338, 436-45.
96. White, J.R.; Lee, J.M.; Young, P.R.; Hertzberg, P.R.; Jurewicz, A.J.; Chaikin, M. A.; Widdowson, K.; Foley, J.J.; Martin, L.D.; Griswold, D.E.; and Sarau, H.M. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J. Biol. Chem., 1998, 273, 10095-8.
97. Keatings, V.M.; Collins, P.D.; Scott, D.M.; and Barnes, P.J. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. J. Respir. Crit. Care Med., 1996, 153, 530-4.
98. Kwon, O.J.; Au, B.T.; Collins, P.D.; Adcock, I.M.; Mak, J.C.; Robbins, R.A.; Baraniuk, J.M.; Chung, K.F.; and Barnes, P.J. Tumor necrosis factor-induced interleukin-8 expression in cultured human airway epithelial cells. Am. J. Physiol., 1994, 11, L398-L405.
99. Thomas, C.E.; Ohlweiler, D.F.; Carr, A.A.; Nieduzak, T.R.; Hay, D.A.; Adams, G.; Vaz, R.; Bernotas, R.C. Characterization of the radical trapping activity of a novel series of cyclic nitrone spin traps. J. Biol. Chem., 1996, 271, 3097-104.
100. Saetta, M.; Baraldo, S.; Corbino, L.; Turato, G.; Braccioni, F.; Rea, F.; Cavallesco, G.; Tropeano, G.; Mapp, C.E.; Maestrelli, P.; Ciaccia, A.; Fabbri, L.M. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 1999, 160, 711-7.
101. Bresser, P.; Out, T.A.; Van Alphen, L.; Jansen, H.M.; Lutter, R. Airway inflammation in nonobstructive and obstructive chronic bronchitis with chronic haemophilus influenzae airway infection. Comparison with noninfected patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2000, 162, 947-52.
102. Nielson, C.P.; Vestal, R.E.; Sturm, R.Z.; and Heasli, P.R. Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J. Allergy Clin. Immunol., 1990, 86, 801-8.
103. Culpitt, S.; Maziak, W.; Loukides, S.; Keller, A.; and Barnes, P.J. Am. J. Respir. Crit. Care Med., 1997, 157, A797.
104. Takanashi, S.; Hasegawa, Y.; Kanehira, Y.; Yamamoto, K.; Fujimoto, K.; Satoh, K.; Okamura, K. Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. Eur. Respir. J., 1999, 14, 309-14.
105. Davenpeck, K.L.; Berens, K.L.; Dixon, R.A.; Dupre, B.; Bochner, B.S. Inhibition of adhesion of human neutrophils and eosinophils to P-selectin by the sialyl Lewis antagonist TBC1269: preferential activity against neutrophil adhesion in vitro. J. Allergy. Clin. Immunol., 2000, 105, 769-75.
106. Noguera, A.; Batle, S.; Miralles, C.; Iglesias, J.; Busquets, X.; MacNee, W.; Agustí, A.G. Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax, 2001, 56, 432-7.
107. Carter, A.B.; Monick, M.M.; Hunninghake, G.W. Both Erk and p38 kinases are necessary for cytokine gene transcription. Am. J. Respir. Cell Mol. Biol., 1999, 20, 751-8.
108. Meja, K.K.; Seldon, P.M.; Nasuhara, Y.; Ito, K.; Barnes, P.J.; Lindsay, M.A.; Giembycz, M.A. p38 MAP kinase and MKK-1 cooperate in the generation of GM-CSF from LPS-stimulated human monocytes by an NF-kappa B-independent mechanism. Br. J. Pharmacol., 2000, 131, 1143-53.
109. Lee, J.C.; Kumar, S.; Griswold, D.E.; Underwood, D.C.; Votta, B.J.; Adams, J.L. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology, 2000, 47, 185-201.
110. Sasaki, T.; Irie-Sasaki, J.; Jones, R. G.; Oliveira-dos-Santos, A.J.; Stanford, W.L.; Bolon, B.; Wakeham, A.; Itie, A.; Bouchard, D.; Kozieradzki, I.; Joza, N.; Mak, T.W.; Ohashi, P.S.; Suzuki, A.; Penninger, J.M. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science, 2000, 287, 1040-6.
111. Stockley, R.A. Neutrophils and protease/antiprotease imbalance. Am. J. Respir. Crit. Care Med., 1999, 160, S49-S52.
112. Shapiro, S.D.; Senior, R.M. Matrix metalloproteinases. Matrix degradation and more. Am. J. Respir. Cell Mol. Biol., 1999, 20, 1100-2.
113. Punturieri, A.; Filippov, S.; Allen, E.; Caras, I.; Murray, R.; Reddy, V.; Weiss, S.J. Regulation of elastinolytic cysteine proteinase activity in normal and cathepsin K-deficient human macrophages. J. Exp. Med., 2000, 192, 789-800.
114. Jorenby, D.E.; Leischow, S.J.; Nides, M.A.; Rennard, S.I.; Johnston, J.A.; Hughes, A.R.; Smith, S.S.; Muramoto, M.L.; Daughton, D.M.; Doan, K.; Fiore, M.C.; Baker, T.B. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med., 1999, 340, 685-91.
115. Rutgers, S.R.; Postma, D.S.; Ten Hacken, N.H.; Kauffman, H.F.; van Der Mark, T.W.; Koëter, G.H.; Timens, W. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax, 2000, 55, 12-8.
116. Sampsonas, F.; Karkoulias, k.; Kaparianos, A.; Spiropoulos, K. Genetics of chronic obstructive pulmonary disease, beyond a1-antitrypsin deficiency. Curr. Med. Chem., 2006, 13, 2857-73.
117. Barnes, P.J. Genetics and pulmonary medicine. 9. Molecular genetics of chronic obstructive pulmonary disease. Thorax, 1999, 54, 245-52.
118. Barnes, P. J. Future Advances in COPD Therapy. Respiration, 2001, 68, 441-8.